Pharmacogenomics, Pharmacokinetics and Circulating Proteins as Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review

by Apostolos Papachristos, Gregory B. Sivolapenko
Published 2020-08-01

<i>VEGF-A</i> and <i>ICAM-1</i> Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

by Apostolos Papachristos, Polychronis Kemos, Theodora Katsila, Eirini Panoilia, George P. Patrinos, Haralabos Kalofonos, Gregory B. Sivolapenko
Published 2019-11-01